TransCode Therapeutics, Inc. (RNAZ)
1.86
+0.15
(+8.77%)
USD |
NASDAQ |
Oct 09, 16:00
1.895
+0.04
(+1.88%)
After-Hours: 20:00
TransCode Therapeutics Enterprise Value : 160.20M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 160.20M |
| October 08, 2026 | 160.05M |
| October 07, 2026 | 160.10M |
| October 06, 2026 | 160.12M |
| October 05, 2026 | 160.10M |
| October 02, 2026 | 159.91M |
| October 01, 2026 | 159.89M |
| September 30, 2026 | 160.02M |
| September 29, 2026 | 159.97M |
| September 28, 2026 | 160.05M |
| September 25, 2026 | 160.03M |
| September 24, 2026 | 159.99M |
| September 23, 2026 | 160.02M |
| September 22, 2026 | 160.11M |
| September 21, 2026 | 160.10M |
| September 18, 2026 | 159.99M |
| September 17, 2026 | 160.06M |
| September 16, 2026 | 160.02M |
| September 15, 2026 | 159.94M |
| September 14, 2026 | 159.99M |
| September 11, 2026 | 160.03M |
| September 10, 2026 | 160.03M |
| September 09, 2026 | 160.12M |
| September 08, 2026 | 160.23M |
| September 04, 2026 | 160.41M |
| Date | Value |
|---|---|
| September 03, 2026 | 160.50M |
| September 02, 2026 | 160.36M |
| September 01, 2026 | 160.41M |
| August 31, 2026 | 160.45M |
| August 28, 2026 | 160.53M |
| August 27, 2026 | 160.63M |
| August 26, 2026 | 160.69M |
| August 25, 2026 | 160.88M |
| August 24, 2026 | 161.05M |
| August 21, 2026 | 161.23M |
| August 20, 2026 | 161.33M |
| August 19, 2026 | 161.57M |
| August 18, 2026 | 161.60M |
| August 17, 2026 | 161.52M |
| August 14, 2026 | 161.64M |
| August 13, 2026 | 161.84M |
| August 12, 2026 | 161.73M |
| August 11, 2026 | 161.79M |
| August 10, 2026 | 162.25M |
| August 07, 2026 | 162.33M |
| August 06, 2026 | 162.64M |
| August 05, 2026 | 162.62M |
| August 04, 2026 | 162.82M |
| August 03, 2026 | 162.59M |
| July 31, 2026 | 162.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.631B |
| Oncolytics Biotech, Inc. | 65.76M |
| Sangamo Therapeutics, Inc. | 52.97M |
| Sarepta Therapeutics, Inc. | 2.143B |
| Anixa Biosciences, Inc. | 85.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.750M |
| Total Expenses (Quarterly) | 6.750M |
| EPS Diluted (Quarterly) | -7.172 |
| Earnings Yield | -2.73K% |
| Normalized Earnings Yield | -2005.59 |